Effect of tacrine hydrochloride on hepatic drug metabolism

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 24, Issue 1, 1999, Pages 91-96

  Danbury, T C ^a   Eccles, M ^a   Ford, J ^a   Roberts, Clive J ^a,b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

Cytochrome P 450; Drug interactions; Drug metabolism; Tacrine

Indexed keywords

CIMETIDINE; CYTOCHROME P450; DRUG METABOLITE; DRUG METABOLIZING ENZYME; ENZYME INHIBITOR; OXIDOREDUCTASE; PHENAZINE DERIVATIVE; PHENAZONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TACRINE;

AEROBIC METABOLISM; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER METABOLISM; LIVER MICROSOME; MALE; NONHUMAN; RAT;

EID: 0032988829     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190016     Document Type: Article

References (29)

1. Neilson J.A., Mena E.E., Williams I.H., Nocerini M.R., Liston D. (1989) : Correlations of brain levels of 9-amino-1,2,3,4-tetrahydroacridine (THA) with neurochemical and behavioural changes. Eur. J. Pharmacol., 173: 53-64.
2. Wills P., Claesson C.B., Fratiglioni L., Fastbom J., Thorslund M. (1997) : Drug use by demented and non-demented elderly people. Age Ageing, 26: 383-391.
3. Breimer D.D. (1983) : Inter individual variations in drug disposition. Clinical implications and methods of investigation. Clin. Pharmacokinet., 8: 371-377.
4. Tanaka E., Kobayashi S., Aramphongphan A. et al. (1985) : The effect of indomethacin on hepatic drug-oxidising capacity in the rat: trimethadione and antipyrine metabolism as an indicator. J. Pharmacobiodyn., 8: 773-779.
5. Statland B.E., Astup P., Black C.H., Oxholm E. (1973) : Plasma antipyrine half-life and hepatic microsomal antipyrine hydroxylase activity in rabbit. Pharmacology, 10: 329-337.
6. McManus M.E., Ilett K.F. (1979) : Comparison of rate of hepatic metabolism in vitro and half-life for antipyrine in vivo in three species. Xenobiotica, 9: 107-118.
7. Boobis A.R., Brodie M.J., Kahn G.C. et al. (1981) : Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man. Br. J. Clin. Pharmacol., 12: 771-777.
8. Buppodorm P., Koga N., Yamada H., Yoshimura H. (1986) : Studies on rat liver cytochrome P-450s involved in the metabolism of antipyrine: phenobarbital- and 3-methylcholanthrene-inducible isoenzymes possessing 4-hydroxylase activity. Biochem. Pharmacol., 35: 1404-1406.
9. Sharer J.E., Wrighton S.A. (1996) : Identification of the human hepatic cytochromes P-450 involved in the in vitro oxidation of antipyrine. Drug Metab. Dispos., 24: 487-494.
10. Somogyi A., Muirhead M. (1987) : Pharmacokinetic interactions of cimetidine. Clin. Pharmacokinet., 12: 321-366.
11. Spaldin V., Madden S., Woolf T.F., Park B.K. (1994) : The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes. Br. J. Clin. Pharmacol., 38: 15-22.
12. Serlin M.J., Sibeon R.G., Mossman S. et al. (1979) : Cimetidine: interaction with oral anticoagulants in man. Lancet, ii: 317-319.
13. O'Reilly R.A. (1984) : Comparative interaction of cimetidine and ranitidine with racemic warfarin in man. Arch. Intern. Med., 144: 989-991.
14. Jackson J.E., Powell J.R., Wandell M., Bentley J., Dorr R. (1981) : Cimetidine decreases theophylline clearance. Am. Rev. Respir. Dis., 123: 615-617
15. Breen K.J., Bury R., Desmond P.V. et al. (1982) : Effects of cimetidine and ranitidine on hepatic drug metabolism. Clin. Pharmacol. Ther., 31: 297-300.
16. Jonkman J.H.G., Upton R.A. (1984) : Pharmacokinetic drug interactions with theophylline. Clin. Pharmacokinet., 9: 309.
17. Rodin E.A., De Sousa G., Haidukewych D., Lodhi R., Berchou R.C. (1984) : Dissociation between free and bound phenytoin levels in the presence of valproate sodium. Arch. Neurol., 38: 240-242.
18. Nation R.L., Evans A.M., Milne R. W. (1990) : Pharmacokinetic drug interactions with phenytoin. Clin. Pharmacokinet., 18: 37 & 131.
19. Vasko M.R., (1990) : Drug interactions. In: Williams R.L., Brater D.C., Mordenti J. (Eds) Rational therapeutics. New York: Marcel Dekker, 175.
20. Watkins P.B., Zimmerman H.J., Knapp M.J., Gracon S.I., Lewis K.W. (1994) : Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA, 271: 992-998.
21. Van Geel C.A.J.F., Van Bezooijen C.F.A. (1990) : The effect of age on the oxidative metabolism of antipyrine by uninduced microsomal fractions of rat liver. Mech. Age. Dev., 53: 169-177.
22. Bradford M. (1976) : A rapid and sensitive method for the quantification of microgram quantities of protein utilising the principle of protein dye binding. Anal. Biochem., 72: 248-254.
23. Boobis A.R., Sesardic D., Murray B.P. et al. (1990) : Species variation in the response of the cytochrome P-450-dependent monooxygenase system to inducers and inhibitors. Xenobiotica, 20: 1139-1161.
24. Murphy F.M., Hardman S.T., Nash R.J. et al. (1991) : Evaluation of HP029 (velnacrine maleate) in Alzheimer's disease. Ann. NY Acad. Sci., 640: 253-262.
25. Eccles M.J., Danbury T.C., Ford J.M., Roberts C.J.C. (1997) : The effect of velnacrine on the mixed function oxidase system. Eur. J. Drug Metab. Pharmacokinet., 22: 121-125.
26. Danhof M., De Groot-Van Der Vis E., Breimer D.D. (1979) : Assay of antipyrine and its primary metabolites in plasma, saliva and urine by HPLC with some preliminary results in man. Pharmacology, 18: 210-223.
27. Inaba T., Lucassen M., Karlow W. (1981) : Antipyrine metabolism in the rat by three hepatic monooxygenases. Life Sci., 26: 1977-1983.
28. Breimer D.D., Vermulen N.P.E., Danhof M., Teunissen M.W.E., Jeroes R.P., Van Der Graff M.L. (1983) : Assessment and prediction of in vivo oxidative metabolising activity. In: Benet L.Z., Levey G., Ferraiolo B.L. (Eds) Pharmacokinetics: a modern view. New York: Plenum, 191-216.
29. Van Der Graaf M., Vermeulen N.P.E., Langendijk P.N.J., Breimer D.D. (1983) : Pharmacokinetics of simultaneously administered hexobarbital and heptabarbital in rats: an alternative approach to metabolic correlation studies. J. Pharmacol. Exp. Ther., 225: 747-751.